Novo Nordisk sees share price rise after winning patent cases

Danish healthcare group Novo Nordisk is celebrating after the US patent office declined to review patents awarded to Novo Nordisk for its weight loss drug Wegovy.

The drug, dubbed an obesity injection, has been a huge comm...

Want to read this article?

Register for ultimate access to this article and ALL our premium content


  • Unrestricted access to Commercial Risk, Commercial Risk Europe and Global Risk Manager news, exclusive expert analysis and opinion
  • Breaking news, daily and/or weekly Commercial Risk Europe newsletters and regular digital publications
  • Breaking news, weekly and monthly Global Risk Manager newsletters and quarterly digital Journal
  • European and global surveys, rankings and special reports
  • National European local language newsletters
  • Preferential access to webinars and virtual and physical conferences

If you are already a registered user or subscriber you can LOGIN below for ultimate access:

Back to top button